Ness Technologies bought by Citi unit for $307m.

CVCI will pay $7.75 per share for Ness, 17.6 percent over the company’s closing price on Nasdaq on Thursday.

June 13, 2011 04:13
1 minute read.

financial graph 311. (photo credit: stock photo)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

IT services and solutions company Ness Technologies Ltd. announced on Friday that Citigroup Inc. unit Citi Venture Capital International will acquire the company for $307 million in cash.

CVCI will pay $7.75 per share for Ness, 17.6 percent over the company’s closing price on Nasdaq on Thursday. Ness’s board of directors recommended that the shareholders approve the deal.

Be the first to know - Join our Facebook page.

Ness CEO Sachi Gerlitz described the acquisition as a new beginning and said that he believed the company would continue to operate. He told Globes, “In my opinion in another four years the company could be in line for a renewed public offering.”

Gerlitz was appointed CEO in 2007, when the company’s market cap was close to a record $600 million, but the company has gone through hard times since then. Ness’s share price tanked as the global economic crisis hit US financial institutions, and the improvement in the company’s 2010 results did not help much.

One reason for the stagnation is the wide range of operations by the 7,000-man company, which the capital market does not care for. In Israel, where Ness began 13 years ago, the company is back on its feet. However, the company’s Central European operations have been hard hit due to the recession there in the past two years, and the performance by the company’s US operations has been poor in the past year, forcing major restructuring in the first quarter of 2011.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection